RECORD AF registry findings were presented at the American Heart Association Scientific Sessions. This registry looked at how newly-diagnosed afib patients were being managed in the real world. These results differed from previously-reported research, such as the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial.
In the real world, more cardiologists chose rhythm drugs over rate drugs for atrial fibrillation treatment. Though clinical outcomes were similar for both, rhythm control showed some advantages, including that far fewer progressed to permanent atrial fibrillation within the year.